Karolinska investors losing patience despite promise of imminent deal
This article was originally published in Scrip
The CEO of Swedish academic investment company Karolinska Development, Torbjörn Bjerke, is clearly feeling the heat of investor wrath. The firm conducted an IPO, listing on NASDAQ OMX Stockholm, in April 2011 raising SEK577 million ($86 million) at SEK43 per share. The company's shares closed yesterday at SEK12.75.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.